Bradley J . Monk, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Affiliate Professor

General

• Levin Gabriel, Gilbert Lucy, Coleman Robert, Ribeiro Reitan, Monk Bradley, Gender and geographic disparity in industry payments to gynecologic oncologists in the United States 2026

Publications

• Gynecologic oncology
  Slomovitz Sadie, Podder Vivek, Campbell-Simms Katie, Slomovitz Brian, Eubanks Rhea, O'Malley David, Randall Leslie, Monk Bradley, Moore Kathleen, Eskander Ramez, Pothuri Bhavana, Copeland Larry, Coleman Robert, Herzog Thomas, Reliability of feasibility surveys for predicting patient accrual in phase III gynecologic trials
  208, p. S142 - S142 2026
• Gynecologic oncology
  Levin Gabriel, Gilbert Lucy, Monk Bradley, Ribeiro Reitan, Coleman Robert, From PARPis to ADCs: Changing patterns of industry payments to gynecologic oncologists
  208, p. S191 - S191 2026
• Gynecologic oncology
  Monk Bradley, Alexandre Jerome, Sánchez Luis Manso, Farolfi Alberto, Braicu Elena Ioana, Madry Radoslaw, Beijers Antoinetta J.M., Vulsteke Christof, Hasegawa Kosei, Wang Jian-Liu, , GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
  208, p. S103 - S104 2026
• Gynecologic oncology
  Monk Bradley, Sebastianelli Alexandra, Zsiros Emese, Mądry Radosław, Kose Fatih, Ibañez Carolina, Korach Jacob, Hasegawa Kosei, Diaz Roberto Ivan Romero, Hudson Emma, , Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study
  208, p. S31 - S31 2026
• Gynecologic oncology
  Grisham Rachel, Thaker Premal, Van Nieuwenhuysen Els, Santin Alessandro, D'Hondt Véronique, Perez-Fidalgo Alejandro, Clamp Andrew, Moore Kathleen, Aghajanian Carol, O'Malley David, Monk Bradley, , Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201
  208, p. S30 - S31 2026
• Gynecologic oncology
  Backes Floor, Barretina-Ginesta Maria-Pilar, Monk Bradley, Forget Frédéric, O'Malley David, Raaschou-Jensen Nicoline, Willmott Lyndsay, Pisano Carmela, O'Cearbhaill Roisin, Follana Philippe, , Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Results from the homologous recombination-deficient (HRd) and -p
  208, p. S25 - S26 2026
• Gynecologic oncology
  Kim Jae-Weon, Lorusso Domenica, Monk Bradley, Gladieff Laurence, Park Jeong-Yeol, Colombo Nicoletta, Muller Carolyn, Olawaiye Alexander, Madrid Lorena Fariñas, Van Gorp Toon, Bertrán Ana Santaballa, Felberbaum Ricardo, Bodnar Lubomir, Pai Sachin, Thaker Premal, Pashova Hristina, Yadav Bhagyashree, Slomovitz Brian, Mallen Adrianne, BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers
  208, p. S107 - S107 2026
• Gynecologic oncology
  Van Gorp Toon, Oaknin Ana, Vergote Ignace, Randall Leslie, Tromp Jacqueline, Lorusso Domenica, Cibula David, Monk Bradley, denys hannelore, Ghamande Sharad, Boere Ingrid, , Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: First disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study
  208, p. S37 - S38 2026
• Gynecologic oncology
  Slomovitz Brian, Alvarez Edwin, Choksi Mamta, Chirnomas Debbie, Crafton Sarah, DiBenedetto Samantha, Niazi Tina, Barlin Joyce, Starks David, Monk Bradley, Eskander Ramez, Wysham Weiya, Jackson Amanda, Lee Christine, Mallen Adrianne, Anderson Charles, Hester Danubia, Rubinstein Maria, Maddocks Oliver, Sapanisertib and serabelisib (PIKTOR) with paclitaxel, and an insulin-suppressing diet (ISD) substudy, in patients with advanced/recurrent endometrial cancer (EC): GOG-3111
  208, p. S105 - S105 2026
• The Lancet (British edition)
  Lorusso Domenica, Gladieff Laurence, O'Malley David M, Gilbert Lucy, Mileshkin Linda, Quesada Stanislas, Hopp Elizabeth, Monk Bradley J, Kim Jae-Weon, Garbaos Gabriel, Fagotti Anna, , Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
  407:10538, p. 1513 - 1524 2026
• The Lancet (British edition)
  Colombo Nicoletta, Bidzinski Mariusz, Gallardo Carlos, Zsiros Emese, Parma Gabriella, Rulli Eliana, Sebastianelli Alexandra, Matanes Emad, Hasegawa Kosei, Kose Fatih, Monk Bradley J, , Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
  407:10538, p. 1525 - 1537 2026
• Targeted therapies in oncology
  Monk Bradley, KEYNOTE-B96 Brings Immunotherapy-Based Option to Platinum-Resistant Ovarian Cancer 2026
• Gynecologic oncology
  Levin Gabriel, Monk Bradley J, Gilbert Lucy, Coleman Robert L, Meyer Raanan, Ribeiro Reitan, Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends
  207S, p. 60 2026
• Gynecologic oncology
  Van Nieuwenhuysen Els, Vergote Ignace, Randall Leslie M, Tromp Jacqueline, Pisano Carmela, Lorusso Domenica, O'Cearbhaill Roisin E, Boere Ingrid, Sanchez Luis Manso, Banerjee Susana, Monk Bradley J, , Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
  207S, p. 3 - 13 2026
• Banerjee Susana, Monk Bradley, Clamp Andrew, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Veronique, Oaknin ANA, The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201 2026
• International journal of gynecological cancer
  Denschlag Dominik, Cloven Noelle, Pennington Kathryn, Monk Bradley J., Powell Matthew A., Roed Henrik, Fleming Evelyn, Gilbert Lucy, Zub Oleksandr, Mccourt Carolyn, Angioli Roberto, , Post-hoc survival outcomes based on initial and subsequent treatment in patients with mmrp/MSS primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
  36:2, p. 104434 2026
• International journal of gynecological cancer
  Konstantinopoulos Panagiotis, Guy Michael, Song Mihae, Eskander Ramez N., Matei Daniela, Winer Ira, Bradley William H., Brubaker Lindsay W., Mcnamara Donna, Turner Rachael, Monk Bradley J., , CLINICAL ACTIVITY OF ACR-368 IN PATIENTS WITH ENDOMETRIAL CARCINOMA PROSPECTIVLY SELECTED BY ONCOSIGNATURE – A PHASE 2 STUDY - ACR-368-201/GOG3082 (NCT05548296)
  36:2, p. 104573 2026
• International journal of gynecological cancer
  González-Martín Antonio, O'Malley David M., Galaz Cristina Churruca, Vulsteke Christof, Chase Dana M., Koliadi Anthoula, Braly Patricia, Lorusso Domenica, Chan John K., D'Hondt Véronique, Willmott Lyndsay J., Monk Bradley J., , Predictors of long-term progression-free survival in patients treated with niraparib first-line maintenance therapy in the phase 3 randomised placebo-controlled PRIMA/ENGOT-OV16/GOG-3012 trial
  36:2, p. 103081 2026
• International journal of gynecological cancer
  Zagouri Flora, Prado Purificación Martinez- Del, Diaz John Paul, Zeng Xing, Lu Chien-Hsing, Jewell Andrea, Salutari Vanda, Van Le Linda, Kuru Oguzhan, Collins Dearbhaile C., Bradford Leslie S., Chudecka-Glaz Anita, Bradley William H., Fujiwara Keiichi, Holloway Robert, Borrow Jen, Ong Valerie, Kristeleit Rebecca S., Monk Bradley J., Rucaparib maintenance in ATHENA-MONO (GOG-3020/ENGOT-ov45) in patients with newly diagnosed advanced ovarian cancer: exploratory post-progression evaluations for patients with HRD-negative and HRD-unknown tumours
  36:2, p. 103090 2026
• International journal of gynecological cancer
  Eminowicz Gemma, Zagouri Flora, Concin Nicole, Mcsorley Lynda M., Tlustý Vojtech, Fujiwara Keiichi, Matanes Emad, Petrella Maria Cristina, Nilsen Elisabeth Berge, Wang Jian Liu, Monk Bradley J., , GOG-3119/ENGOT-en29/TROFUSE-033: A phase 3, randomised study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
  36:2, p. 104392 2026
• JCO precision oncology
  Coleman Robert L, Wallraven Gladice, Willoughby David, Nagel Casey, Wei Qi, Horvath Staci, Stanbery Laura, Rocconi Rodney, Monk Bradley J, Walter Adam, Nemunaitis John, Tang Min, Rao Donald, Bognar Ernest, Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer
  10:10, p. e2500462 2026
• Graybill Whitney S, Pardo Búrdalo Beatriz, O’Malley David M, Copeland Larry J, Sabbatini Roberto, Herzog Thomas J, Follana Philippe, Auranen Annika, Monk Bradley J, Vergote Ignace, , Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study 2025
• Future oncology (London, England)
  Banerjee Susana N, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley J, Clamp Andrew, D'Hondt Véronique, Rodrigues Manuel, Chon Hye Sook, Holloway Robert W, Colombo Nicoletta, Gennigens Christine, Newman Gregg, Salinas Erin, Youssoufian Hagop, Santin Alessandro D, O'Malley David M, Gourley Charlie, Thaker Premal H, Van Gorp Toon, Grisham Rachel N, Lustgarten Stephanie, Prendergast Emily, Oaknin Ana, Ring Kari, Moore Kathleen N, The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201, p. 1 2025
• Moore Kathleen, Grisham Rachel, Fabbro MICHEL, OMalley David, Monk Bradley, Van Nieuwenhuysen Els, GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer 2025
• International journal of gynecological cancer
  Eskander Ramez N., Slomovitz Brian, Makker Vicky, Fujiwara Keiichi, Moore Kathleen N., Monk Bradley, Gonzalez-Martin Antonio, Oza Amit, Oaknin Ana, Leary Alexandra, Ali Talal, Sehouli Jalid, Rider Alex, Brown Tom, Smith Alan, Gourley Charlie, REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
  35:11, p. 102488 2025
• International journal of gynecological cancer
  Hasegawa Kosei, Arkhipov Alexander, Yañez Eduardo, Gumus Mahmut, Hurtado De Mendoza Mivael Olivera, Samouëlian Vanessa, Castonguay Vincent, Tekin Cumhur, Toker Sarper, Monk Bradley, Li Kan, Colombo Nicoletta, Tewari Krishnansu S., Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Shapira-Frommer Ronnie, Salman Pamela, PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826
  35:11, p. 102156 2025
• International journal of gynecological cancer
  Lee Elizabeth, Yeku Oladapo, Call Justin, Winer Ira, Richardson Debra, Seamon Leigh, Hamilton Erika, Monk Bradley, Cloven Noelle, Zhang Jian, Kavalerchik Edward, PART C OF RAINFOL™-01: A PHASE 1/2 STUDY OF SINGLE-AGENT RINATABART SESUTECAN IN PATIENTS WITH ADVANCED AND/OR METASTATIC PLATINUM-RESISTANT OVARIAN CANCER
  35:11, p. 102616 2025
• International journal of gynecological cancer
  Richardson Debra, Weiner Ira, Willmott Lyndsay J., Call Justin, Pepin Jessica Thomes, Jewell Andrea, Mathews Cara, Seamon Leigh, Buscema Joseph, Monk Bradley, Guancial Elizabeth, Orr Douglas, Melnyk Anton, Gillespie Michael, Kilavuz Nurgul, Ong Teng Jin, Kavalerchik Edward, Cloven Noelle, Konecny Gottfried, Lee Elizabeth, RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
  35:11, p. 102612 2025
• International journal of gynecological cancer
  Salani Ritu, Lee Jung-Yun, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Duska Linda, Van Gorp Toon, Boere Ingrid, Marth Christian, Mądry Radosław, Zagouri Flora, Monk Bradley, Li Xin Tong, Bogusz Agata M., Toker Sarper, Lindemann Kristina, Cáceres M. Valeria, Harter Philipp, Zhongqiu Lin, Valabrega Giorgio, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Canova Stefania, TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
  35:11, p. 102609 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Sill Michael, Lankes Heather, Leitao Mario, Ramondetta Lois, Clair Kiran, Newton Meredith, Guntupalli Saketh, Iii Charles Leath, Richardson Debra, Disilvestro Paul, Cantuaria Guillerme, Billingsley Caroline, Mcdonald Megan, Liu Yingmiao, Starr Mark, Birrer Michael, Monk Bradley, Brady Chris, Lea Jayanthi, Ueland Frederick, Chambers Laura, Tewari Krishnansu S., Nixon Andrew, PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
  35:11, p. 102158 2025
• International journal of gynecological cancer
  Nicum Shibani, Marth Christian, Lu Chien-Hsing, Monk Bradley, Crafton Sarah, Zagouri Flora, Segev Yakir, Collins Dearbhaile C., Kümmel Jan, Petrella Maria Cristina, Lassus Heini J., Fujiwara Keiichi, Wang Jian Liu, Jaishuen Atthapon, Cáceres M. Valeria, Freitas-Junior Ruffo, Kruger Stephan, Black Destin, Slomovitz Brian M., Orlowski Robert, Yao Lili, GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER
  35:11, p. 102611 2025
• International journal of gynecological cancer
  Vergote Ignace, Cibula David, Perez Fidalgo Jose Alejandro, Valabrega Giorgio, Monk Bradley, Herzog Thomas, Colombo Nicoletta, Pothuri Bhavana, Sehouli Jalid, Korach Jakob, Richardson Debra, Barlin Joyce, Papadimitriou Christos, Van Gorp Toon, Mccarthy Michael, Antill Yoland, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert, ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
  35:11, p. 102472 2025
• International journal of gynecological cancer
  Lorusso Domenica, Monk Bradley, Martin Lainie, Schenker Michael, Maximiano Constanza, Barlin Joyce, Kim Yong Man, Bese Tugan, Rose Peter G., Chang Chih-Long, Pospiskova Marketa, Salinas Erin A., Malander Susanne, Santin Alessandro D., Collins Dearbhaile C., Willmott Lyndsay, Craib Marcia, Chui Joshua, Fujiwara Keiichi, Kristeleit Rebecca, SAFETY OF RUCAPARIB MONOTHERAPY IN ADVANCED HIGH-GRADE OVARIAN CANCER CLINICAL TRIALS
  35:11, p. 102262 2025
• Gynecologic oncology
  Chase Dana M, Cho Chi Heum, Kim Jae-Weon, No Jae Hong, Smick Alexandra H, Holman Laura, Stuckey Ashley, Fabian Denise, Wenzel Lari, Gil Karen, Ryu Sang Young, Mayadev Jyoti, Huang Helen Q, Deng Wei, Koh Wui-Jin, Rodgers William, Small, Jr William, Albuquerque Kevin, Leath Charles A, Kim Dae-Yeon, Monk Bradley, Kim Beob-Jong, Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)
  202, p. 102 - 109 2025
• Journal of clinical oncology
  Monk Bradley J, Coleman Robert L, O'Malley David M, Moore Kathleen N, González-Martín Antonio, Herzog Thomas J, Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer, p. JCO2501721 2025
• Molecular cancer therapeutics
  Leary Alexandra, Willmott Lyndsay, Monk Bradley J., Frenel Jean-Sébastien, Starks David C., Okera Meena, Secord Angeles Alvarez, O’Malley David M., Martin Lainie, Ouali Kaissa, Oehler Martin K., Goh Jeffrey C., Slomovitz Brian M., Lim Peter C., Shannon Catherine M., Neff Robert, Backes Floor J., Rajendran Divya, Chung Heekyung, Kim Doris, Li Hailun, Jandial Danielle, Simpkins Fiona, Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
  24:10_Supplement, p. B013 - B013 2025
• Annals of oncology
  Kristeleit R S, Yeku O, Pisano C, Buscema J, Demirkiran F, Ueland F, Chudecka-Głaz A, Prendergast E, Kim Y B, Fuentes Pradera J, Oaknin A, Provencher D, Zagouri F, Martin L P, Chou H-H, Eskander R N, Beiner M, Anderson C, Drochytek V, O'Malley D M, Littell R D, Gao B, Valabrega G, Shih D, Agarwal R, Maloney L, Despain D, Connor C, Craib M, Fujiwara K, Dean A, Lisyanskaya A, Monk B J, Ghamande S, Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study 2025
• Journal of clinical oncology
  Banerjee Susana N, D'Hondt Véronique, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley J, Clamp Andrew, Prendergast Emily, Holloway Robert W, Oaknin Ana, Ring Kari, Colombo Nicoletta, Rodrigues Manuel, Chon Hye Sook, Gennigens Christine, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Newman Gregg, Salinas Erin, Youssoufian Hagop, Moore Kathleen N, Lustgarten Stephanie, O'Malley David M, Van Gorp Toon, Grisham Rachel N, Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2502377 2025
• Obstetrical & gynecological survey
  Olawaiye Alexander B., Vergote Ignace, Kesner-Hays Amanda, Pashova Hristina I., Pai Sachin G., Tudor Iulia Cristina, Jubb Adrian M., Lorusso Domenica, O'Malley David M., Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Artioli Grazia, Caruso Giuseppe, Nicum Shibani, Bagameri Andrea, Bodnar Lubomir, Kim Byoung-Gie, Colombo Nicoletta, De La Creva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, do Carvalho Calabrich Aknar Freire, Cassani Chiara, You Benoit, Churruca Cristina, Hopp Elizabeth, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Leiser Aliza L., McCollum Michael E., Diakos Connie, Clamp Andrew, Balazs Boglárka, Monk Bradley J., Scandurra Giuseppa, Van Gorp Toon, Kang Sokbom, Gladieff Laurence, Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
  80:10, p. 636 - 638 2025
• Annals of oncology
  Ryu S Y, Leath, 3rd C A, Gil K M, Small, Jr W, Rodgers W, Deng W, Albuquerque K, Koh W-J, Fabian D, Chase D M, Miller K, Mannel R S, Monk B J, Mayadev J, Heugel A, Kim J-W, Kim B-J, Kim D-Y, Cho C-H, No J H, Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008 2025
• Konstantinopoulos Panagiotis A, Kim Jae Weon, Freyer Gilles, Colombo Nicoletta, Lee Jung Yun, Gaba Lydia, Grisham Rachel N, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Friedlander Michael, Cibula David, Monk Bradley J, Nyvang Gitte Bettina, Lorusso Domenica, Van Nieuwenhuysen Els, Malik Rozita, Cortés-Salgado Alfonso, Glasspool Rosalind, Marth Christian, Leary Alexandra, Zamagni Claudio, Marmé Frederik, Sufliarsky Jozef, Su Fei, Zuradelli Monica, Wang Craig, Hinson Patsy, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Primary Analysis of EPIK-O/ENGOT-ov61:Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation 2025
• Gynecologic oncology
  Levin Gabriel, Pothuri Bhavana, Monk Bradley, Coleman Robert, Herzog Thomas, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to drug approvals for gynecologic malignancies by the Food and Drug Administration
  200, p. 150 2025
• Gynecologic oncology
  Lee Elizabeth, Call Justin, Winer Ira, Hamilton Erika, Yeku Oladapo, Richardson Debra, Seamon Leigh, Cloven Noelle, Zhang Jian, Kavalerchik Edward, Monk Bradley, Part C of a phase I/II study evaluating single agent rinatabart sesutecan in patients with advanced and/or metastatic platinum-resistant ovarian cancer
  200, p. 112 - 113 2025
• Gynecologic oncology
  File Brittany, Herzog Thomas, Coleman Robert, Tewari Krishnansu, Kapp Daniel, Monk Bradley, Richardson Michael, Francoeur Alex, Tran Nathan, Chan John, Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years
  200, p. 114 - 115 2025
• Gynecologic oncology
  Salani Ritu, Lindemann Kristina, Kurtz J. Emmanuel, Zhongqiu L.I.N., Nishio Shin, Oaknin Ana, Valabrega Giorgio, Canova Stefania, Cáceres M. Valeria, Lee Jung-Yun, Harter Philipp, Gilbert Lucy, Sadozye Azmat, Van Gorp Toon, Boere Ingrid, Marth Christian, Duska Linda, Madry Radoslaw, Zagouri Flora, do Rêgo Barros Lilian Arruda, Monk Bradley, Li Xin Tong, Bogusz Agata, Toker Sarper, Mirza Mansoor, TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical c
  200, p. 121 - 122 2025
• Gynecologic oncology
  Richardson Michael, Kapp Daniel, Chan John, Herzog Thomas, Coleman Robert, Monk Bradley, Gynecologic cancers in tumor-agnostic trials: Keys to regulatory approval
  200, p. 74 2025
• Gynecologic oncology
  Bujnak Alyssa, Hamilton Alina, Hari Anjali, Hoadley Katherine, Lankes Heather, Monk Bradley, Birrer Michael, Sill Michael, Ramirez Nilsa, Szot Christopher, Wei Lei, Tewari Krishnansu, Huang Helen, Landrum Lisa, Liu Hongwei, Penson Richard, Ramondetta Lois, Michael Helen, Oaknin Ana, Reid Thomas, Leitao Mario, Copeland Larry, Jones Corbin, Reeves Catherine, Predictive biomarkers for chemotherapy plus bevacizumab in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 National Institutes of Health Cancer Moonshot
  200, p. 352 - 353 2025
• Gynecologic oncology
  Lee Jung-Yun, Gilbert Lucy, Oaknin Ana, Lorusso Domenica, Kim Kidong, Lee Yeh Chen, Gao Bo, Tan David, Monk Bradley, Oza Amit, Miller Rowan, O'Malley David, Pothuri Bhavana, Lu Lin, Berman Craig, Borgman Anne, Naumann Wendel, Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
  200, p. 351 2025
• Annals of oncology
  Mercieca-Bebber R., Holschneider C., Buck M., Brooks S., Lea J., Stuckey A., Lad T.E., Spirtos N., Boyd L., Fyles A., Monk B., King M.T., Stockler M., Mileshkin L., Moore K., Barnes E., Diamante K., Lee Y.C., Narayan K., Khaw P., 1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial
  36, p. S772 - S773 2025
• Annals of oncology
  Lorusso D., Muller C.Y., Monk B.J., Park J-Y., Colombo N., Van Gorp T., Kim J-W., Gladieff L., Olawaiye A., Madrid L. Fariñas, Bertrán A. Santaballa, Felberbaum R., Bodnar L., Pai S., Thaker P.H., Pashova H.I., Yadav B.K., Mallen A., 1239eTiP BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer
  36, p. S748 - S748 2025
• Annals of oncology
  Monk B.J., Lorusso D., Van Nieuwenhuysen E., Tromp J., Zikan M., O'Cearbhaill R.E., Banerjee S., Collins D.C., Jackson A.L., Madsen K., Gennigens C., Baurain J-F., Ottevanger P.B., Ghamande S., Salutari V., Reyners A., Conte U., Windfeld K., Hansen H., Vergote I., 1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
  36, p. S769 - S770 2025
• Gynecologic oncology
  Chase Dana, Monk Bradley, Small William, Huang Helen, Deng Wei, Rodgers William, Mayadev Jyoti, Leath Charles, Kim Beob-Jong, Albuquerque Kevin, Kim Dae-Yeon, Cho Chi-Heum, Gil Karen, Fabian Denise, Ryu Sang Young, Kim Jae-Weon, No Jae Hong, Holman Laura, Stuckey Ashley, Smick Alexandra, Wenzel Lari, Patient-reported outcomes on a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate-risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy (NCT#01101451)
  200, p. 4 - 5 2025
• Gynecologic oncology
  Simpkins Fiona, Leary Alexandra, Willmott Lyndsay, Monk Bradley, Frenel Jean-Sebastien, Goh Jeffrey, Slomovitz Brian, Lim Peter, Shannon Catherine, Neff Robert, Kim Doris, Li Hailun, Jandial Danielle, Backes Floor, Starks David, Okera Meena, Secord Angeles Alvarez, O'Malley David, Martin Lainie, Ouali Kaissa, Oehler Martin, Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
  200, p. 8 - 9 2025
• Gynecologic oncology
  Ryu Sang Young, Albuquerque Kevin, Deng Wei, Koh Wui-Jin, Mayadev Jyoti, Heugel Anne, Kim Beob-Jong, Miller Katherine, Kim Dae-Yeon, Cho Chi-Heum, Kim Jae-Weon, No Jae Hong, Mannel Robert, Fabian Denise, Small William, Rodgers William, Leath Charles, Monk Bradley, Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical carcinoma following radical hysterectomy and lymphadenectomy: Results of NRG oncology/GOG-263
  200, p. 4 2025
• Gynecologic oncology
  Grisham Rachel, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley, Clamp Andrew, D’hondt Veronique, Derio Silvia, Prendergast Emily, Oaknin Ana, Ring Kari, Holloway Robert, Rodrigues Manuel, Chon Hye Sook, Gourley Charlie, Santin Alessandro, Thaker Premal, Gennigens Christine, Newman Gregg, Moore Kathleen, Lustgarten Stephanie, O'Malley David, Salinas Erin, Youssoufian Hagop, Van Gorp Toon, Banerjee Susana, ENCORE: Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis
  200, p. 34 - 35 2025
• Cancer treatment and research communications
  Monk Bradley J., Gordan Lucio N., Patel Manish R., Toker Sarper, Subbiah Vivek, DEVELOPMENT OF ANTI-CANCER MEDICINES IN THE CURRENT ERA, p. 101002 - 101002 2025
• International journal of gynecological cancer
  Podder Vivek, Coleman Robert L., Eskander Ramez, Flint Michelle, Monk Bradley J., Slomovitz Brian M., Checkpoint Inhibitor Rechallenge in Advanced Endometrial Cancer: Revisiting the Immune Landscape Beyond First-Line Therapy, p. 102124 2025
• Journal of clinical oncology
  Konstantinopoulos Panagiotis A, Su Fei, Hinson Patsy, Zuradelli Monica, Wang Craig, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Freyer Gilles, Kim Jae Weon, Lee Jung Yun, Wu Xiaohua, Gaba Lydia, Grisham Rachel N, Colombo Nicoletta, Monk Bradley J, Sehouli Jalid, Cruz Felipe, Cibula David, Van Nieuwenhuysen Els, Nyvang Gitte-Bettina, Friedlander Michael, Lorusso Domenica, Leary Alexandra, Malik Rozita, Glasspool Rosalind, Marth Christian, Sufliarsky Jozef, Cortés-Salgado Alfonso, Zamagni Claudio, Marmé Frederik, Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation, p. JCO2500225 2025
• Journal of clinical oncology
  Banerjee Susana N, Monk Bradley J, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Véronique, Prendergast Emily, Oaknin Ana, Ring Kari, Clamp Andrew, Gennigens Christine, Colombo Nicoletta, Holloway Robert W, Rodrigues Manuel, Chon Hye Sook, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Moore Kathleen N, Newman Gregg, Salinas Erin, Youssoufian Hagop, Grisham Rachel N, Lustgarten Stephanie, O'Malley David M, Van Gorp Toon, , Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2500112 2025
• Gynecologic oncology
  Chan John K., Tewari Krishnansu, McHale Michael T., Monk Bradley J., Herzog Thomas J., Coleman Robert L., Richardson Michael T., Salani Ritu, Francoeur Alex A., Kapp Daniel S., Optimizing therapy for cervical cancers – Translating trial data into clinical decision-making
  199, p. 47 - 50 2025
• Annals of oncology
  Mayadev J, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Estevez-Diz M D P, Limaye S, Xin W, Shapira-Frommer R, Stewart R A, Dry H, Broggi M A S, Yuan D Y, Monk B J, Varga S, Ramírez Godinez F J, Leiva M, Cetina-Pérez L D C, Molina Alavez A, Alarcon-Rozas A E, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Vázquez Limón J C, Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses 2025
• The Lancet (British edition)
  Olawaiye Alexander B, Artioli Grazia, Gladieff Laurence, O'Malley David M, Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Caruso Giuseppe, Nicum Shibani, Bagaméri Andrea, Kesner-Hays Amanda, Bodnar Lubomir, Kang Sokbom, Vergote Ignace, Jubb Adrian M, Pashova Hristina I, Pai Sachin G, Tudor Iulia Cristina, Hopp Elizabeth, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Lorusso Domenica, Kim Byoung-Gie, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Clamp Andrew, Colombo Nicoletta, McCollum Michael E, Diakos Connie, Scandurra Giuseppa, Leiser Aliza L, Balázs Boglárka, Monk Bradley J, De La Cueva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, de Carvalho Calabrich Aknar Freire, Churruca Cristina, Cassani Chiara, You Benoit, Van Gorp Toon, Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 2025
• International journal of gynecological cancer
  Lightfoot Michelle DS, Lutz Kathleen, Rubinstein Maria M., Monk Bradley J., Eskander Ramez N., Moore Kathleen N., Herzog Thomas J., Pothuri Bhavana, Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment, p. 101997 2025
• Journal of clinical oncology
  Bujnak Alyssa, Birrer Michael J., Hamilton Alina, Sill Michael, Monk Bradley J., Hari Anjali, Penson Richard T., Lankes Heather A., Hoadley Katherine A., Liu Hongwei, Szot Christopher, Ramondetta Lois M., Oaknin Ana, Leitao Mario Mendes, Copeland Larry J., Ramirez Nilsa C., Wei Lei, Tewari Krishnansu Sujata, miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot
  43:16_suppl, p. 5523 - 5523 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Alvarez Ronald D., Small Michelle N., Randall Leslie M., Mannel Robert S., Mutch David, Coleman Robert L., Herzog Thomas J., Monk Bradley J., Moore Kathleen N., Copeland Larry J., Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.’s Scholar Career Development Award and New Investigator Program, p. 101982 2025
• Journal of clinical oncology
  Shahin Mark S., Moore Richard G., Hietanen Sakari, O’Cearbhaill Roisin E., Mangili Giorgia, Berton Dominique, Rubio-Pérez Maria Jesús, Burger Robert Allen, Braicu Elena Ioana, Monk Bradley J., Shtessel Luda, Cloven Noelle, Aaquist Haslund Charlotte, Herzog Thomas J, Lim Jonathan, Gonzalez Martin Antonio, McCormick Colleen C., Barretina-Ginesta Maria-Pilar, O’Malley David M., Honhon Brigitte, Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC)
  43:16_suppl, p. 5551 - 5551 2025
• Journal of clinical oncology
  Mayadev Jyoti, Vázquez Limón Juan Carlos, RamIrez Godinez Francisco Javier, Leiva Manuel, Alarcon-Rozas Ashley Efrain, Cetina Lucely Del Carmen, Varga Szilvia, Molina Alavez Alejandro, Valdivieso Natalia, Wu Xiaohua, Limaye Sewanti Atul, Mandai Masaki, Shapira-Frommer Ronnie, Estevez-Diz Maria Del Pilar, Xin Wenjing, Broggi Maria, Stewart Ross, Monk Bradley J., Yuan Daniel Y., Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses
  43:16_suppl, p. 5502 - 5502 2025
• Journal of clinical oncology
  Salani Ritu, Lin Zhongqiu, Lindemann Kristina, Mirza Mansoor Raza, Nishio Shin, Cáceres Valeria, Oaknin Ana, Kurtz Jean Emmanuel, Valabrega Giorgio, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat, De Rêgo Barros Lilian Arruda, Boere Ingrid A., Li Xin Tong, Marth Christian, Duska Linda R., Monk Bradley J., Tekin Cumhur, , TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer
  43:16_suppl 2025
• Journal of clinical oncology
  Mercieca-Bebber Rebecca, Lee Yeh Chen, Barnes Elizabeth H., Moore Kathleen N., Fyles Anthony, Narayan Kailash, Khaw Pearly, Buck Martin, Brooks Susan, Holschneider Christine, Lea Jayanthi Sivasothy, Stuckey Ashley, Lad Thomas E., Spirtos Nicola M., Stockler Martin R., Boyd Leslie R., Small William, Monk Bradley J., Mileshkin Linda R., King Madeleine T., Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial
  43:16_suppl, p. 5503 - 5503 2025
• ESMO open
  Oaknin A., Fujiwara K., Kristeleit R., Monk B.J., Schenker M., Prendergast E., Salutari V., Littell R., Martinez-Garcia J., Yeku O., Ueland F., Lee J-Y., De Vivo R., Dean A., Diaz J., Bese T., Jewell A., Van Gorp T., Maloney L., 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
  10 2025
• ESMO open
  Okines A., Oh D-Y., Curigliano G., Mizuno N., Rorive A., Hamilton E.P., Soliman H., Takahashi S., Bekaii-Saab T., Monk B.J., Nakamura Y., Nguyen D., O'Malley D., Reck M., Tan Q., Yu E., Drees A., Ramos J.D., Stinchcombe T., Pohlmann P.R., 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
  10, p. 104876 2025
• International journal of gynecological cancer
  Podder Vivek, Cobb Lauren Patterson, Grisham Rachel N., Coleman Robert L., Monk Bradley J., Herzog Thomas, Gershenson David M., Slomovitz Brian M., Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment, p. 101938 2025
• Cancer treatment reviews
  Monk Bradley J., Sehouli Jalid, Lorusso Domenica, Fujiwara Keiichi, Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review, p. 102945 2025
• Gynecologic oncology
  Matulonis Ursula A., Mahner Sven, Berton Dominique, Berek Jonathan S., Redondo Andrés, Herrstedt Jørn, Oza Amit, Marmé Frederik, Haslund Charlotte A., Lindahl Gabriel, Tinker Anna V., Ledermann Jonathan A., Benigno Benedict, Mirza Mansoor R., González-Martín Antonio, Bécourt Stéphanie, Bains Manjinder, Colombo Nicoletta, Malinowska Izabela A., Liu Wenlei, Monk Bradley J., ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
  195, p. 192 2025
• Gynecologic oncology
  Leath, 3rd Charles A, Holman Laura L, Deng Wei, Mell Loren K, Richardson Debra L, Walker Joan L, Arend Rebecca C, Lea Jayanthi S, Amarnath Sudha R, Santos-Reyes Luis Javier, Chon Hye Sook, Mayadev Jyoti, Jegadeesh Naresh, DiSilvestro Paul, Chino Junzo P, Ghamande Sharad A, Gao Lei, Albuquerque Kevin, Quick Allison M, Donnelly Eric, Feddock Jonathan M, Lowenstein Jessica, Kunos Charles M, MacKay Helen, Aghajanian Carol, Monk Bradley J, Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
  195, p. 122 - 133 2025
• Gynecologic oncology
  Carter Jeanne, Huang Helen Q, Monk Bradley J, Kim Yong-Beom, Kim Moon-Hong, Stuckey Ashley, Vicus Danielle L, Holman Laura L, Fleury Aimee C, Pearson J Matthew, Thawani Nitika, Shahin Mark, Lea Jayanthi, Robertson Sharon E, Warshal David, Backes Floor J, Feltmate Colleen, Wilkinson-Ryan Ivy, Covens Allan, Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
  195, p. 50 2025
• Gynecologic oncology
  Covens Allan, DiSilvestro Paul, Monk Bradley J, Kim Yong-Beom, Kim Moon-Hong, Huang Helen Q, Fleury Almee, Pearson J Matthew, Thawani Nitika, Vicus Danielle, Holman Laura L, Shahin Mark S, Lea Jayanthi S, Robertson Sharon E, Feltmate Colleen, Dewdney Summer, Leitao Mario M, Wilkinson-Ryan Ivy, Warshal David, Backes Floor, Elsayed Ahmed G, Carter Jeanne, Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
  195, p. 59 2025
• International journal of gynecological cancer
  Leitao Mario M., Eskander Ramez N., Randall Leslie M., Bixel Kristin L., Chase Dana Meredith, Quick Allison, McCormick Colleen, Black Destin, Lim Peter C., Gotlieb Walter H., LoCoco Salvatore, Martino Martin A., Walker Joan L., Copeland Larry J., Monk Bradley J., ROCC/GOG-3043: A randomized controlled trial of robotic versus open surgery for early-stage cervical cancer, p. 101760 2025
• International journal of gynecological cancer
  Salani Ritu, Lindemann Kristina, Lin Zhongqiu, Valabrega Giorgio, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Cáceres M. Valeria, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Boere Ingrid, Marth Christian, Mirza Mansoor Raza, Monk Bradley J., Li Xin Tong, Tekin Cumhur, Duska Linda, TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
  35:2, p. 100497 2025
• International journal of gynecological cancer
  Ghamande Sharad, Prendergast Emily, Miller Rowan E., Solovyeva Ekaterina, Del Mar Gordon Santiago Maria, Kim Yong-Man, Littell Ramey, Fujiwara Keiichi, Anttila Maarit, Connor Christy, Craib Marcia, Monk Bradley J., Kristeleit Rebecca S., Turna Hande, Ruiz Nuria, Bessette Paul, Van Le Linda, Westin Shannon N., Zvaríková Mária, Eskander Ramez N., ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100319 2025
• International journal of gynecological cancer
  Lokich Elizabeth, Jørgensen Trine Lembrecht, Black Destin, Cibula David, Gilbert Lucy, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gill Sarah E., Monk Bradley J., Nevadunsky Nicole, Cloven Noelle, Podzielinski Iwona, Myers Tashanna, Dabrowski Christine, Ring Kari L., Stevens Shadi, Willmott Lyndsay, Mirza Mansoor Raza, Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
  35:2, p. 101722 2025
• European journal of cancer (1990)
  Vergote Ignace, Thaker Premal H., Van Gorp Toon, Laenen Annouschka, Scambia Giovanni, Cibula David, Colombo Nicoletta, Lea Jayanthi, Monk Bradley J., Gonzalez-Martin Antonio, Korach Jacob, Sehouli Jalid, Heinzelmann-Schwarz Viola, Berger Regina, Buscema Joseph, Lau Susie, Mądry Radoslaw, Denys Hannelore, Pepin Jessica Thomes, Salutari Vanda, Bagaméri Andrea, Ardizzoia Antonio, Copeland Larry J., Hruda Martin, Iglesias David A., Manso Luis, Shai Ayelet, O’Malley David M., Cecere Sabrina Chiara, Henry Stéphanie, Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study, p. 115306 2025
• International journal of gynecological cancer
  Lorusso Domenica, Pothuri Bhavana, Monk Bradley J., Barretina-Ginesta Maria-Pilar, Vergote Ignace, O’malley David M., Haslund Charlotte A., Heitz Florian, O’cearbhaill Roisin E., Abadie-Lacourtoisie Sophie, Backes Floor J., Chase Dana M., Amit Amnon, Moore Kathleen N., Malinowska Izabela A., Graybill Whitney S., Herzog Thomas J., Golembesky Amanda K., Rubio Pérez Maria-Jesús, González-Martín Antonio, Updated Patient-Reported Outcomes In The PRIMA/ENGOT-OV26/GOG-3012 Trial Of Niraparib First-Line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100093 2025
• Therapeutic advances in medical oncology
  Powell Matthew A, Novák Zoltán, Black Destin, Gilbert Lucy, Sharma Sudarshan, Stuckey Ashley, Boere Ingrid, Gold Michael A, Segev Yakir, Pothuri Bhavana, Monk Bradley J, Shahin Mark S, Grimshaw Matthew, Stevens Shadi, Lai Dominic W, McCourt Carolyn, Mirza Mansoor Raza, Buscema Joseph, Coleman Robert L, Gennigens Christine, Sebastianelli Alexandra, Gill Sarah E, Valabrega Giorgio, Landrum Lisa M, Gropp-Meier Martina, Slomovitz Brian M, Ring Kari L, Herzog Thomas J, Balas Morad Marco, Bjørge Line, Willmott Lyndsay, A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
  17, p. 17588359251342241 2025
• Journal of gynecologic oncology
  Kim Yong-Man, Tewari Krishnansu S., Hasegawa Kosei, Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Kim Se Ik, Lee Jeong-Won, Liou Wen-Shiung, Li Kan, Nishio Shin, Tekin Cumhur, Colombo Nicoletta, Monk Bradley J., Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
  36 2025
• Mirza Mansoor R, Chase Dana M, Slomovitz Brian M, Gilbert Lucy, Coleman Robert L, Powell Matthew A, Christensen René de Pont, Novák Zoltán, Black Destin, Sharma Sudarshan, Valabrega Giorgio, Landrum Lisa M, Gold Michael A, Hanker Lars C, Stuckey Ashley, Boere Ingrid, Auranen Annika, Raspagliesi Francesco, Pothuri Bhavana, Cibula David, McCourt Carolyn, Shahin Mark S, Gill Sarah E, Monk Bradley J, Stevens Shadi, Copeland Larry J, Tian Min, He Zangdong, Buscema Joseph, Herzog Thomas J, Zografos Eleftherios, A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer” 2025
• Annals of oncology
  González-Martín A, Malinowska I A, Monk B J, Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al 2024
• Annals of oncology
  Lorusso D, Colombo N, Dubot C, Cáceres M V, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera M, Toker S, Castonguay V, Arkhipov A, Li K, Samouëlian V, Tekin C, Tewari K S, Monk B J, Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024
• International journal of gynecological cancer
  Barlin Joyce, Eshed Helen, Black Destin, Cottrill Hope, Hand Lauren, Durbin Joan, O’Malley David, Chuang Linus, Chisamore Michael, Zheng Pan, Lim Peter, Pepin Jessica Thomes, Hopp Elizabeth, Cloven Noelle, Monk Bradley, Liu Yang, Shpyro Svetlana, LB010/#1590  A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
  34, p. A6 - A8 2024
• International journal of gynecological cancer
  Lorusso Domenica, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Collins Dearbhaile, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• International journal of gynecological cancer
  Grisham Rachel, Monk Bradley, O’Malley David, Van Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, Colombo Nicoletta, Oaknin Ana, Thaker Premal, Oza Amit, Lustgarten Stephanie, Youssoufian Hagop, Banerjee Susana, PR029/#943  A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
  34, p. A53 - A54 2024
• International journal of gynecological cancer
  Bixel Kristin, Baiocchi Glauco, Black Destin, Lococo Salvatore, Eskander Ramez, Gotlieb Walter, Lee Sun Joo, Randall Leslie, Martino Martin, Mccormick Colleen, Monk Bradley, Quick Allison, Walker Joan, Leitao Mario, Chase Dana, TP001/#1584  GOG-3043 (nct04831580): a randomized non-inferiority trial of robotic versus open surgery for early stage cervical cancer (ROCC)
  34, p. A347 - A347 2024
• International journal of gynecological cancer
  Oaknin Ana, Lorusso Domenica, Lee Jung-Yun, Pietzner Klaus, Schilder Russell, Cibula David, Lee Yeh Chen, Auranen Annika, Gao Bo, Salutari Vanda, Tan David, Oza Amit, Miller Rowan, Pothuri Bhavana, Tasca Giulia, O’Malley David, Monk Bradley, Wendel Naumann R., Lu Lin, Berman Craig, Borgman Anne, TP010/#1537  Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
  34, p. A351 - A351 2024
• International journal of gynecological cancer
  Banerjee Susana, Youssoufian Hagop, Kalbacher Elsa, Van Gorp Toon, Lustgarten Stephanie, Van Nieuwenhuysen Els, Grisham Rachel, Aghajanian Carol, Santin Alessandro, Ring Kari, Colombo Nicoletta, Chon Hye Sook, Thaker Premal, Prendergast Emily, Moore Kathleen, Cortés-Salgado Alfonso, Clamp Andrew, O’malley David, Monk Bradley, Fabbro Michel, LB007/#1548  Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
  34, p. A13 - A13 2024
• International journal of gynecological cancer
  Vergote Ignace, Colombo Nicoletta, Korach Jacob, Barlin Joyce, Papadimitriou Christos A, Li Kai, Kalyanapu Pratheek, Valabrega Giorgio, Monk Bradley J, Herzog Thomas, Perez Fidalgo Alejandro, Cibula David, Pothuri Bhavana, Sehouli Jalid, van Gorp Toon, Richardson Debra, McCarthy Michael, Antill Yoland, Mirza Mansoor Raza, Slomovitz Brian, Coleman Robert L, ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: ratio
  34:8, p. 1283 2024
• Chan John, Monk Bradley, McNally Leah, Richardson Michael, Tian Chunqiao, Kesterson Joshua, Lin Ken, Darcy Kathleen, Kapp Daniel, Landrum Lisa, Copeland Larry, Phippen Neil, Berry Laurel, Bell Jeffery, Walker Joan, Wenham Robert, Spirtos Nick, Tewari Krishnansu, Shahin Mark, Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study 2024
• Gynecologic oncology
  Valabrega Giorgio, Graybill Whitney S, Pothuri Bhavana, Oaknin Ana, Tinker Anna V, Sánchez Ana Beatriz, McCormick Colleen, Baurain Jean-François, Moore Richard G, Denys Hannelore, O'Cearbhaill Roisin E, Hietanen Sakari, Knudsen Anja Ør, González-Martín Antonio, de La Motte Rouge Thibault, Heitz Florian, Levy Tally, York Whitney, Gupta Divya, Monk Bradley J, Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• Gynecologic oncology
  Randall Leslie M., Gaillard Stephanie, Holloway Robert W., Huang Marilyn, O'Malley David M., Monk Bradley J., Coleman Robert L., Adams Sarah, Duska Linda R., Dalton Heather, , Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
  178, p. 161 - 169 2023
• Journal of clinical oncology
  Gourley Charlie, Buscema Joseph, Dalton Heather J., Banerjee Susana N., Lockley Michelle, Krell Jonathan, Monk Bradley J., PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer
  36:15_suppl, p. TPS5612 - TPS5612 2018